Engineered EV Therapy for Chronic Wounds
Chronic Non-Healing Wounds (e.g., Diabetic Foot Ulcers)
Pre-clinicalActive
Key Facts
Indication
Chronic Non-Healing Wounds (e.g., Diabetic Foot Ulcers)
Phase
Pre-clinical
Status
Active
Company
About Tozho
Tozho is a private, pre-clinical biotech firm founded in 2021, based in San Francisco, developing engineered extracellular vesicle (EV) therapies for chronic wound care. Its core technology involves engineering mesenchymal stem cell-derived EVs with CD47 for immune evasion and encapsulating therapeutic enzymes like thymidine phosphorylase to promote angiogenesis and healing. The company is in the early stages, building its platform and advancing towards therapeutic candidates, with a proprietary, scalable manufacturing process aimed at future clinical translation.
View full company profile